Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML July 23, 2025
CoRegen announced the close of a $93,390,000 million financing to advance CMC development July 15, 2025
AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for First-in-Class CD38×BCMA×CD3 Trispecific Antibody ISB 2001 July 15, 2025
Oxford BioTherapeutics Announces Third Oncology Drug Candidate from Boehringer Ingelheim Collaboration Selected to Advance into IND-Enabling Studies July 15, 2025
Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development July 15, 2025
HanchorBio and Henlius Sign Major Licensing Deal for HCB101 to Expand Global Immuno-Oncology Reach July 8, 2025
Oxford BioTherapeutics Announces Third Oncology Drug Candidate from Boehringer Ingelheim Collaboration Selected to Advance into IND-Enabling Studies July 8, 2025
Revolution Medicines and Summit Therapeutics to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors July 1, 2025
Sanofi to advance Kymera’s next-gen oral IRAK4 degrader KT-485 into clinical testing and will not advance KT-474 July 1, 2025
Hummingbird Bioscience Licenses HMBD-002, Ph 2-Ready Anti-VISTA Monoclonal Antibody, to Percheron Therapeutics July 1, 2025
Revolution Medicines and Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for RAS-Addicted Cancers July 1, 2025
Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders July 1, 2025
Xcell Biosciences and Thermo Fisher Scientific to Advance the Next Generation of Cell Therapies July 1, 2025
Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers June 25, 2025
